General description
Valdecoxib (VCX) is a diaryl substituted isoxazole compound. It comprises of sulfonyl propanamide and is a metabolite of parecoxib.
Application
Valdecoxib may be used: as cyclooxygenase-2 (COX-2) inhibitor in fibroblast cells, as an analyte for mass spectrometry analysis, as an standard in ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) for quantification of valdecoxib in plasma samples
Biochem/physiol Actions
Valdecoxib is reported to elicit anti-inflammatory, analgesic and antipyretic functionality. It acts as a substrate for the liver enzyme cytochrome P450 2C9(CYP2C9) and cytochrome P450 3A4 (CYP3A4).
Valdecoxib is a non-steroidal anti-inflammatory drug (NSAID), a cyclooxygenase-2 (COX-2) selective inhibitor.
Other Notes
This compound was developed by Pfizer for Lipid Signaling research. To learn more about Sigma′s partnership with Pfizer and view other authentic, high-quality Pfizer compounds, visit sigma.com/bsm-pfizer.
To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Legal Information
Sold for research purposes under agreement from Pfizer Inc.
Pfizer is a registered trademark of Pfizer, Inc.
- UPC:
- 51172168
- Condition:
- New
- Availability:
- 3-5 Days
- Weight:
- 1.00 Ounces
- HazmatClass:
- No
- MPN:
- PZ0179-25MG
- CAS:
- 181695-72-7
